Previous in vitro studies have demonstrated that LAG1 longevity assurance homolog 2 (LASS2) is a novel tumor suppressor gene that is significantly associated with the proliferation and invasion ability of tumor cells. However, the role LASS2 serves in regulating bladder cancer cell tumorigenicity and tumor growth in vivo has not yet been elucidated in animal or clinical studies. In the present study, LASS2 knockdown in human bladder cancer EJ-M3 cells significantly promoted the growth of xenografts in nude mice compared with the control group, while overexpression of LASS2 suppressed tumor growth; however, this was not statistically significant. Furthermore, LASS2 knockdown resulted in more apparent heteromorphism and a higher activity of matrix metalloproteinase (MMP)-2 and MMP-9 in xenograft tumors. The data from the present study demonstrated that LASS2 knockdown significantly promoted the tumorigenicity and growth of EJ-M3 xenograft tumors in nude mice, and that LASS2 overexpression has a tendency to inhibit the growth of xenografts, suggesting that it may be a potential therapeutic target for bladder cancer.
Introduction
Bladder cancer is one of the most common malignant tumors of the urinary system and is a major cause of mortality worldwide. An estimated 429,800 cases of bladder cancer are diagnosed every year and 165,100 mortalities occurred in 2012 worldwide as a result of the disease (1) . In the United States of America, a total of 79,030 new bladder cancer cases and 16,870 bladder cancer-associated mortalities were projected to occur in 2017 (2, 3) . Therefore, the identification of genes associated with bladder cancer and novel therapeutic targets is necessary.
LAG1 longevity assurance homolog 2 (LASS2), also known as tumor metastasis suppressor gene 1, was identified as a tumor suppressor gene (3) . LASS2 has been correlated with the degree of invasion and recurrence of carcinomas of the prostate (4-6), liver (7) , breast (8, 9) and bladder (10) . However, to the best of our knowledge, the precise role LASS2 serves in regulating bladder cancer cell tumorigenicity and growth in vivo has not yet been investigated in animal or clinical studies.
In previous studies, an implantation metastasis model of the highly invasive human bladder cancer EJ-M3 cell line was established in nude mice (11, 12) . Another study identified that LASS2 expression was the highest in the EJ-M3 cell line compared with other human bladder carcinoma cell lines (BIU-87, T24 and EJ), and was significantly correlated with the proliferation, metastasis and invasion of human bladder cancer (13) . In the present study, EJ-M3 cells were selected for a lentivirus-mediated LASS2 interference strategy and LASS2 overexpression, in order to investigate the effects of LASS2 expression on bladder cancer cell tumorigenicity and growth in vitro and in nude mice.
Fisher Scientific, Inc., Waltham, MA, USA), 100 U/ml penicillin and 100 µg/ml streptomycin at 37˚C in a humidified atmosphere with 5% CO 2 . All reagents were purchased from EMD Millipore (Billerica, MA, USA).
Construction of the lentiviral vector and cell transfection.
EJ-M3 cells were transfected with a LASS2 shRNA plasmid (cat no. HSH008629-CU6) or a LASS2 overexpression plasmid (cat no. EX-T3019-M98-5) (both GeneCopoeia, Inc., Rockville, MD, USA). Briefly, the plasmids were amplified in DH5α Escherichia coli cells (Takara Biotechnology Co., Ltd., Dalian, China), purified using an E.Z.N.A.
® Endo-Free Plasmid Mini Kit I (Omega Bio-Tek, Inc., Norcross, GA, USA), and transfected into 80% confluent EJ-M3 cells using Lipofectamine ® 2000 (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). A lentiviral vector expressing green fluorescent protein (GFP) alone was used as the control. At 72 h following transfection, LASS2 overexpression and LASS2 shRNA positive cells were selected using 1 µg/ml neomycin or puromycin, respectively, and the transfection efficiency was examined by fluorescence microscopy (Olympus BX53; Olympus Corporation, Tokyo, Japan).
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. Total RNA was extracted from cells using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.), and reverse transcribed into cDNA using Quant Reverse Transcriptase (Tiangen Biotech Co., Ltd., Beijing, China) following the manufacturer's protocol. β-Actin was used as the internal control. RT-qPCR was performed in a 20 µl reaction containing 1 µl cDNA template, 1 µl primer and 10 µl FastStart Universal SYBR Green Master (ROX) (Roche Ltd., Mannheim, Germany), using an Applied Biosystems 7900HT Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific Ltd., Waltham, MA, USA). The primers sequences were as follows: β-actin forward, 5'-GAA GGT GAA GGT CGG AGT C-3'; and reverse, 5'-GAA GAT GGT GAT GGG ATT TC-3'; LASS2 forward, 5'-TCT CCT GGT TTG CCA ATT ACG-3'; and reverse, 5'-CCG GGC AGG GAC CCT CAT CA-3'. All the primers were synthesized by GeneCopoeia, Inc. The amplification program consisted of denaturation at 95˚C for 1 min, followed by 40 cycles of denaturation at 95˚C for 15 sec and annealing at 60˚C for 30 sec, and then extension at 60˚C for 30 sec. All experiments were repeated at least three times. The relative expression of LASS2 mRNA was calculated using the 2 -ΔΔCq method (14) . cell group (LASS2-over); and a LASS2-shRNA EJ-M3 cell group (LASS2-shRNA). All nude mice were housed in a sterile environment with a room temperature of 20-25˚C, a relative humidity of 30-70% and a 12 h light/dark cycle. All mice were given free access to food and water, and the bedding materials, drinking water, feeding cages and other items in contact with the animals were all autoclaved prior to use. Cell suspensions (200 µl, 2x10 6 /ml) of non-transfected, LASS2-over or LASS2-shRNA EJ-M3 cells were subcutaneously injected into the right side of the dorsal aspect of the nude mice using a 6-gauge needle. The tumor size and body weight of each mouse were measured once a week. The tumor volumes were calculated using the following formula: V=π/6 x largest diameter x smallest diameter 2 (15) , and tumor growth curves were plotted. The tumor inhibition rate (TIR) was determined using the formula: TIR (%)=[1-(mean tumor volume of experimental group/mean tumor volume of control group)]x100. All mice were sacrificed 6 weeks following injection, and the tumors were resected. One part of each tumor was fixed in 4% formalin, dehydrated with gradient alcohol, cleared with xylene, embedded in paraffin, sectioned serially (4-µm-thick sections), and then mounted on a slide for hematoxylin and eosin staining and immunohistochemical analysis. Another part of each tumor was stored at -80˚C for the detection of matrix metalloproteinase (MMP)-2/-9 activity. The slides were stained with hematoxylin and eosin (H&E), and the properties of the xenograft tumors were assessed under an optical microscope (Eclipse E200; Nikon Corporation, Tokyo, Japan).
Immunohistochemical analysis. The slides were heated and subsequently put in xylene, washed with gradient alcohol for deparaffinization, and then rehydrated with distilled water. After that, antigen retrieval was performed in 1 mM boiling EDTA buffer (pH 8.0; EMD Millipore) for 15 min at 92-100˚C. The slides were incubated with 3% hydrogen peroxide for 30 min, washed, and blocked with 5% goat serum (EMD Millipore) for 60 min at room temperature. A mouse monoclonal anti-LASS2 antibody (cat. no. sc-390745; dilution, 1:100, Santa Cruz Biotechnology, Inc.) was applied to each slide overnight at 4˚C. Following washing with PBS (pH 7.4), the slides were incubated for 30 min with a rabbit anti-mouse secondary antibody (cat. no. A-11062, dilution, 1:400; Invitrogen; Thermo Fisher Scientific, Inc.). Subsequently, the slides were stained with diaminobenzidine, counterstained with hematoxylin, dehydrated in ethanol, cleared in xylene, mounted on coverslips and examined under an optical microscope (Eclipse E200; Nikon Corporation, Tokyo, Japan). The cells with yellow-brown staining in their cytoplasm were considered LASS2-positive. The mean density of staining, calculated using Image Pro-Plus (Media Cybernetics, Inc., Rockville, MD, USA) as previously described (16) , was used to quantify the LASS2 staining.
MMP zymography. To investigate MMP-2 and MMP-9 activity in the xenografts expressing different LASS2 levels, gelatin zymography was used. SDS-PAGE on a 10% gel containing 0.1 mg/ml gelatin was used for electrophoresis. The protein samples (20 µg of each) were loaded into each lane, and electrophoresis was performed at 100 V for 1.5 h at 4˚C. Subsequently, the gel was washed twice with 100 ml solution containing 2.5% Triton X-100 on a rotary shaker for 40 min at room temperature, then incubated in 100 ml reaction buffer (50 mmol/l Tris-HCl, 5 mmol/l CaCl 2 , 0.02% NaN 3 , pH 7.6) for 42 h at 37˚C. Following staining with Coomassie brilliant blue and destaining with methanol and acetic acid, the gels were scanned using the BioSpectrum Imaging System (BioSpectrum 510; UVP, Inc., Upland, CA, USA), and the relative activities of MMP-2 and MMP-9 were quantified by densitometric analysis of the zymograms using ImageJ software (National Institutes of Health, Bethesda, MD, USA).
Statistical analysis. All data were expressed as the mean ± standard deviation. Statistical analyses were performed using SPSS software (version 19.0; IBM SPSS, Armonk, NY, USA). A one-way analysis of variance followed by a Tukey's multiple comparison test was used to evaluate the differences between the groups. P<0.05 was considered to indicate a statistically significant difference.
Results

Expression of LASS2 in EJ-M3 cells following transfection
with a LASS2 shRNA construct or a LASS2 overexpression plasmid. To confirm transfection efficiency, fluorescence microscopy was used to detect the expression of GFP in EJ-M3 cells transfected with a LASS2 shRNA construct or a LASS2 overexpression plasmid 72 h following transfection (Fig. 1A) . Non-transfected EJ-M3 cells expressing GFP alone were used as the Con group. Subsequently, the cells were collected to detect the expression of LASS2 at the mRNA and protein levels by RT-qPCR and western blot analysis, respectively. β-Actin was used as the internal control for normalization. The RT-qPCR results demonstrated that LASS2 expression in the LASS2-shRNA group was significantly decreased by 39% (P<0.001), while that in the LASS2-over group was significantly increased by 263% (P<0.001), compared with the Con group (Fig. 1B) . A western blot analysis demonstrated similar results at the protein level (Fig. 1C and D) . These results demonstrate that the two different recombinant LASS2 plasmids were successfully transfected into the EJ-M3 cells.
Knockdown or overexpression of LASS2 significantly affects bladder tumor growth in vivo.
To determine the functional role of LASS2 in human bladder cancer initiation and progression, EJ-M3 cells transfected with LASS2 shRNA constructs or LASS2 overexpression plasmids were subcutaneously injected into the right side of the dorsal aspect of the neck of nude mice. Non-transfected EJ-M3 cells were injected as the Con group. Tumor growth and body weight were closely monitored during the following weeks (Fig. 2) . Ten days following injection, palpable subcutaneous xenografts were observed in all nude mice, and the tumor incidence rates in the three groups were 100%. Tumor growth curves demonstrated that the xenografts grew significantly faster in the LASS2-shRNA group compared with both the LASS2-over and Con groups (both P<0.001); however, no significant difference was observed between the LASS2-over and Con groups (P>0.05) (Fig. 2A) . No animals died during the observation period. Six weeks following injection, all mice were sacrificed and the tumors were removed. All subcutaneous xenografts exhibited oval or nodal shapes with a smooth surface (Fig. 2C and D) . The tumor volumes of the LASS2-shRNA, LASS2-over and Con groups were 222.32±124.97, 41.01±15.97 and 69.60±31.37 mm 3 , respectively. Compared with the Con group, the TIRs in the LASS2-shRNA and LASS2-over groups were -219.42 and 41.08%, respectively (data not shown). These results indicate that LASS2 knockdown significantly increases tumor volume, while LASS2 overexpression does not significantly affect tumor growth when compared with the Con group, despite a trend for LASS2 overexpression to decrease tumor volume (P= 0.821; Fig. 2E ). During the experimental period, LASS2 knockdown had a tendency to reduce the body weight of nude mice; however, there was no significant difference in body weight between these three groups (Fig. 2B) .
H&E staining confirmed the subcutaneous xenografts as bladder transitional cell carcinoma. The tumor cells exhibited a nest-like distribution, apparent heteromorphism, and large and irregular nuclei with obvious nucleoli, particularly in the LASS2-shRNA group (Fig. 3A) . Additionally, immunohistochemical analysis was used to detect LASS2 expression levels in the xenografts. There was a significantly higher mean density of LASS2-positive cells in the LASS2-over group compared with those in the LASS2-shRNA and Con groups (P<0.001; Fig. 3B and C) . These results suggest that different LASS2 expression levels regulate the tumorigenicity of bladder cancer EJ-M3 cells, the growth of xenografts and the degree of tumor cell heteromorphism in vivo.
Effect of LASS2 expression on MMP-2 and MMP-9 activity in xenografts.
Using gelatin zymography and a quantified analytical system, MMP-2 and MMP-9 activity in the xenografts with different LASS2 expression levels was analyzed. MMP-2 and MMP-9 expression levels were identified as clear bands against a lighter blue background (Fig. 4A) . Compared with the Con group, the relative activities of MMP-2 ( Fig. 4B ) and MMP-9 (Fig. 4C) in the LASS2-shRNA group were significantly higher (P<0.0001), while those in the LASS2-over group were significantly lower (P<0.0001).
Discussion
LASS2 serves an important role in inhibiting the proliferation and invasion of a number of tumor cancer cell lines, including those of the prostate, liver and breast (7, 17, 18) . Previous studies have suggested that LASS2 inhibits tumor invasion and metastasis through the inhibition of vacuolar-H(+)-ATPase by LASS2 through its association with the V-type proton ATPase 16 kDa proteolipid subunit (the C subunit of V-ATPase) may subsequently suppress the activation of hydrogen sensitive P<0.01 vs. the Con group. LASS2, LAG1 longevity assurance homolog 2; Con, control; LASS2-over, LASS2 overexpression group; shRNA, short hairpin RNA.
proteolytic enzymes and the degradation of extracellular matrix, inducing apoptosis of tumor cells (4) (5) (6) (7) 19, 20) . Previous studies have also revealed that V-ATPase serves a critical role in the secretion and activation of degradation enzymes, such as MMPs (21, 22) .
LASS2 has been demonstrated to promote tumor cell apoptosis via the synthesis of ceramide (3, 23, 24) . Tang et al (7) transiently transfected HCCLM3 cells with a pCMV-HA2-LASS2 plasmid in order to increase the expression of LASS2, and the results suggested that LASS2 overexpression inhibits the migration and invasion of HCCLM3 cells. Lu et al (25) demonstrated that the risk of hepatocellular carcinoma was elevated in 1-month-old mice in which LASS2 had been knocked out. Previous studies have demonstrated that LASS2 expression is downregulated and associated with poor clinical prognosis in advanced human bladder carcinoma (26) , and that LASS2 expression is significantly correlated with diverse proliferation, metastasis and invasion in bladder cancer cells (13) . Another previous study revealed that LASS2 overexpression downregulated the expression of apoptosis regulator Bcl-2 and survivin, while LASS2 siRNA upregulated their expression (27) . A recent study by our group demonstrated that LASS2 overexpression in the bladder cancer EJ cell line resulted in a decrease in cell proliferation, metastasis and invasion ability in vitro (28) . These results are in agreement with the previous studies discussed above.
Recent studies have revealed that the silencing of LASS2 in a number of tumor cell lines increases tumor growth and lymph node metastases in vivo (20, 29) . In the present study, the results of RT-qPCR and Western blot analyses confirmed that the EJ-M3-LASS2-knockdown cells and EJ-M3-LASS2-overexpression cells were successfully established by transfecting LASS2-shRNA or LASS2 overexpression plasmids into the human bladder cancer EJ-M3 cell line. The cell suspensions were subcutaneously injected into the right dorsal aspect of the neck of the nude mice in order to observe xenograft tumor growth. According to the results of the tumor growth curves produced and the TIRs calculated, LASS2 knockdown in human bladder cancer EJ-M3 cells significantly promoted the growth of xenografts in nude mice. Additionally, H&E staining and the xenograft experiments suggested that different LASS2 expression levels affect the degree of tumor cells heteromorphism.
Data from the present study demonstrated that LASS2 overexpression had a tendency to inhibit the growth of xenografts; however, this result was not statistically significant. Previous studies have demonstrated that LASS2 overexpression inhibits tumor growth in vivo; for example, Fan et al (8) demonstrated that the combination of LASS2 overexpression and doxorubicin significantly inhibited the growth of xenografts in nude mice. Additionally, several previous studies have revealed that reducing MMP-2 and MMP-9 activity inhibited tumorigenicity and the growth of xenografts in nude mice. For example, Xu et al (30) reported that the silencing of LASS2 may promote invasion of human prostate cancer cell in vitro by increasing the activity of secreted MMP-2. Consistently, Mei et al (18) reported that the overexpression of LASS2 could inhibit the invasion of the human breast cancer cell line MCF-7 in vitro by suppressing MMP-2 activation and extracellular matrix degradation. In addition, a recent study has revealed that MMP-9 knockdown inhibited tumorigenicity in nude mice (31). In order to further investigate the influence of LASS2 overexpression on the growth of bladder tumor xenografts, LASS2 expression and MMP-2/-9 activity in the xenografts was detected using immunohistochemistry and gelatin zymography, respectively. The activities of MMP-2 and MMP-9 were negatively correlated with LASS2 expression in the xenografts of nude mice. These results suggest that LASS2 overexpression significantly suppresses the activities of MMP-2 and MMP-9 in vivo, which is consistent with the results of previous studies (18, 20, 30) .
The data from the present study revealed that LASS2 overexpression had a tendency to inhibit the growth of bladder tumor xenografts, though this was not statistically significant. However, the activities of MMP-2 and MMP-9 were significantly decreased in LASS2 overexpression xenografts compared with the Con. Additionally, there was a wide variability in tumor volumes within the same groups. There are several possible explanations for this, such as that the mechanisms of tumorigenicity and tumor growth in vivo are complex, including gene-gene interaction and multiple factors involved in tumor formation, growth and metastasis. Another possible explanation is the short observation period and the small sample size of the present study. Therefore, further research is required to confirm whether LASS2 overexpression inhibits tumor growth.
In conclusion, the results from the present study indicate that LASS2 knockdown enhances the heteromorphism of EJ-M3 cell xenograft tumors and promotes the tumorigenicity and growth of tumors in vivo. In addition, LASS2 overexpression was identified to have a tendency to inhibit the growth of xenografts, suggesting that it is a potential therapeutic target for bladder cancer.
